JP2019537582A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537582A5
JP2019537582A5 JP2019522710A JP2019522710A JP2019537582A5 JP 2019537582 A5 JP2019537582 A5 JP 2019537582A5 JP 2019522710 A JP2019522710 A JP 2019522710A JP 2019522710 A JP2019522710 A JP 2019522710A JP 2019537582 A5 JP2019537582 A5 JP 2019537582A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
hearing loss
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058834 external-priority patent/WO2018081614A1/en
Publication of JP2019537582A publication Critical patent/JP2019537582A/ja
Publication of JP2019537582A5 publication Critical patent/JP2019537582A5/ja
Pending legal-status Critical Current

Links

JP2019522710A 2016-10-31 2017-10-27 シナプス形成および神経突起形成を増強するための方法 Pending JP2019537582A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662415101P 2016-10-31 2016-10-31
US62/415,101 2016-10-31
US201762488740P 2017-04-22 2017-04-22
US62/488,740 2017-04-22
US201762510596P 2017-05-24 2017-05-24
US62/510,596 2017-05-24
US201762550345P 2017-08-25 2017-08-25
US62/550,345 2017-08-25
PCT/US2017/058834 WO2018081614A1 (en) 2016-10-31 2017-10-27 Methods for enhancing synaptogenesis and neuritogenesis

Publications (2)

Publication Number Publication Date
JP2019537582A JP2019537582A (ja) 2019-12-26
JP2019537582A5 true JP2019537582A5 (cg-RX-API-DMAC7.html) 2020-12-03

Family

ID=62020809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522710A Pending JP2019537582A (ja) 2016-10-31 2017-10-27 シナプス形成および神経突起形成を増強するための方法

Country Status (5)

Country Link
US (2) US10576125B2 (cg-RX-API-DMAC7.html)
EP (1) EP3532042A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019537582A (cg-RX-API-DMAC7.html)
CN (1) CN110248650A (cg-RX-API-DMAC7.html)
WO (1) WO2018081614A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076330B2 (en) 2018-04-27 2024-09-03 The Regents Of The University Of California Inhibition of lipofuscin aggregation by molecular tweezers
JP2021522282A (ja) 2018-04-27 2021-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California リソソーム蓄積障害の治療
WO2019213245A1 (en) * 2018-05-03 2019-11-07 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
EP3849530A4 (en) * 2018-09-12 2022-06-22 Hough Ear Institute METHODS OF TREATMENT OF HEARING LOSS AFTER COCHLEAR IMPLANT SURGERY
CN113811358A (zh) * 2019-03-26 2021-12-17 通尼克斯制药控股有限公司 S-(n,n-二乙基氨基甲酰基)谷胱甘肽的盐形式
WO2020243478A1 (en) * 2019-05-29 2020-12-03 Massachusetts Eye And Ear Infirmary Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss
CN112939823A (zh) * 2019-12-10 2021-06-11 中国石油天然气股份有限公司 泥页岩抑制剂制备方法及抑制剂的应用
WO2025245095A1 (en) * 2024-05-20 2025-11-27 Therapeutic Vision, Inc. Method of preventing blast-induced loss of cochlear and vestibular hair cells and auditory spiral ganglion neurons

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US6064064A (en) * 1996-03-01 2000-05-16 Fire Sentry Corporation Fire detector
HK1040053B (en) 1998-09-25 2007-09-21 Cephalon, Inc. Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
BRPI1009871A2 (pt) * 2009-03-27 2016-03-08 Moleac Pte Ltd terapia para promover o crescimento celular
CA2772097C (en) * 2009-08-24 2019-04-30 Hough Ear Institute Methods for treating acute acoustic trauma
WO2012106654A1 (en) * 2011-02-04 2012-08-09 Hough Ear Institute Methods for treating brain injury
EP2872128B1 (en) * 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
EP2892506B1 (en) * 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
JP6396438B2 (ja) * 2013-06-04 2018-09-26 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
WO2017048778A1 (en) * 2015-09-18 2017-03-23 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier

Similar Documents

Publication Publication Date Title
US12336974B2 (en) Methods and compositions for preventing and treating auditory dysfunctions
RU2469726C2 (ru) Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
JP2014511374A5 (cg-RX-API-DMAC7.html)
JP2007513079A5 (cg-RX-API-DMAC7.html)
JP2013521231A5 (cg-RX-API-DMAC7.html)
JP2015522630A5 (cg-RX-API-DMAC7.html)
JP2018522938A (ja) 難聴の処置のためのセトロンファミリーのカルシニューリン阻害剤
Lin et al. Experimental animal models of drug-induced sensorineural hearing loss: a narrative review
JP2019511496A5 (cg-RX-API-DMAC7.html)
JP2019513814A5 (cg-RX-API-DMAC7.html)
CN117919232B (zh) 吲哚丙酸在治疗肝硬化以及免疫性肝损伤的应用
JP2019537582A (ja) シナプス形成および神経突起形成を増強するための方法
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2006524243A5 (cg-RX-API-DMAC7.html)
JP2018505218A5 (cg-RX-API-DMAC7.html)
JP2018512451A5 (cg-RX-API-DMAC7.html)
JP2021523126A5 (cg-RX-API-DMAC7.html)
US20210137861A1 (en) Methods for reducing accumulated pathologic tau protein
CN118787626A (zh) 一种d-丝氨酸化合物在制备神经调节剂和治疗脑功能障碍药物中的应用
AU2020376223B2 (en) Combination therapy having antioxydant properties
WO2023079954A1 (ja) 内耳性難聴の抑制又は予防のためのエルゴチオネインを含む組成物
TWI858583B (zh) 組成物於製備用於預防或治療聽力缺損的藥物的用途
RU2640133C1 (ru) Применение пептида thr-lys-pro-arg-pro-gly-pro (селанк) для профилактики и лечения токсического гепатита
JP2010540661A5 (cg-RX-API-DMAC7.html)
US20110207689A1 (en) The treatment of hearing loss